{
    "clinical_study": {
        "@rank": "151532", 
        "acronym": "ENTICHIR", 
        "arm_group": {
            "arm_group_label": "Dicrofenac", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "PG-analogues induce hyperemia as one of side effects in addition to IOP reduction.\n\n      IOP reduction is caused by direct FP receptor stimulation, but the cause of hyperemia is not\n      clarified.\n\n      Because FP receptor stimulation induce intrinsic production of PGs, hyperemia or IOP\n      reduction may be due to secondary induced PGs.\n\n      Thus, pretreatment with NSAID may affect the PG-analogue induced hyperemia or IOP reduction."
        }, 
        "brief_title": "Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes", 
        "completion_date": {
            "#text": "December 2008", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hyperemia", 
            "Intraocular Pressure"
        ], 
        "condition_browse": {
            "mesh_term": "Hyperemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. normal healthy eye\n\n          2. not applicable for IOP level\n\n          3. not wearing contact lenses\n\n          4. not applicable for the presence of the ocular surface diseases in case the treatment\n             was not needed\n\n        Exclusion Criteria:\n\n          1. the eyes with chronic or recurrent uveitis, scleritis, corneal herpes infection\n\n          2. the eyes with the history of trauma, intraocular surgery, or Laser surgery within 6\n             months\n\n          3. the eyes with difficulty for the measurement of IOP with the applanation tonometer\n\n          4. the subjects with the allergy for PG-analogues or benzalkonium chloride\n\n          5. the subjects using the eyedrops excluding those in this study\n\n          6. the subjects treated with oral carbonic anhydrase inhibitor\n\n          7. the subject with Sjogren syndrome\n\n          8. the subjects who can not drop periodically\n\n          9. the subjects with the advanced glaucoma or the terminal stage of glaucoma\n\n         10. the subjects with the severe ocular complications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 20, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02136589", 
            "org_study_id": "CS-097"
        }, 
        "intervention": {
            "arm_group_label": "Dicrofenac", 
            "description": "dicrofenac drop 3 times a day travoprost 0.005% once daily", 
            "intervention_name": "dicrofenac and travoprost", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Inflammatory Agents", 
                "Diclofenac", 
                "Travoprost"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 12, 2014", 
        "number_of_arms": "1", 
        "official_title": "Effect of Non-steroid Anti-inflammatory Drug on Travoprost-induced Conjunctival Hyperemia and Intraocular Pressure Reduction in Normal Eyes", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "effect of NSAID on IOP reduction by travoprost", 
            "measure": "IOP reduction", 
            "safety_issue": "Yes", 
            "time_frame": "1 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02136589"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tokyo University", 
            "investigator_full_name": "Makoto Aihara", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Tokyo University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tokyo University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}